Abzena PLC Result of AGM (7821Q)

TIDMABZA

RNS Number : 7821Q

Abzena PLC

14 September 2017

Abzena plc

Result of Annual General Meeting

Cambridge, UK, 14 September 2017: Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing services and technologies to enable better biopharmaceutical products, announces that at its Annual General Meeting held today at 10am on the Babraham Research Campus in Cambridge, all resolutions were duly passed on a show of hands.

Details of the votes received in relation to each of the resolutions (which are more particularly described in the Notice of Annual General Meeting dated 28 July 2017) are as follows:

 
 Resol   Vote For      % In      Votes Against   % Against   Votes      % Abstain   Total Votes 
                        favour                                Abstain 
------  ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   1     153,588,233   100       0               0           0          0           153,588,233 
------  ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   2     153,588,233   100       0               0           0          0           153,588,233 
------  ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   3     153,588,233   100       0               0           0          0           153,588,233 
------  ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   4     153,588,233   100       0               0           0          0           153,588,233 
------  ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   5     153,588,233   100       0               0           0          0           153,588,233 
------  ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   6     153,588,233   100       0               0           0          0           153,588,233 
------  ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   7     153,588,233   100       0               0           0          0           153,588,233 
------  ------------  --------  --------------  ----------  ---------  ----------  ------------ 
   8     153,588,233   100       0               0           0          0           153,588,233 
------  ------------  --------  --------------  ----------  ---------  ----------  ------------ 
 

Percentage figures have been subject to rounding as considered appropriate.

The total number of ordinary shares of GBP0.002 each eligible to be voted at the Annual General Meeting was 213,639,236.

Enquiries:

 
   Abzena plc 
    John Burt, Chief Executive Officer Julian 
    Smith, Chief Financial Officer                   [phone] 
   Numis (Nominated Adviser and Broker) 
    Clare Terlouw / James Black / Paul Gillam        [phone] 
 
   N+1 Singer (Joint Broker) 
    Aubrey Powell / Liz Yong                         [phone] 
   Instinctif Partners                               [phone] 
    Melanie Toyne Sewell / Alex Shaw                  [e-mail] 
 

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

   --   Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --   Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

   --   Proprietary site-specific conjugation technologies and novel payloads for ADC development; and 
   --   GMP manufacturer of ADC linkers, payloads & combined linker-payloads. 

For more information, please see www.abzena.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGSFEFFLFWSELU

(END) Dow Jones Newswires

September 14, 2017 07:46 ET (11:46 GMT)